 Carboplatin and paclitaxel are chosen as the chemotherapy back bone since they are commonly used in combination in multiple tumors. Cetuximab has been chosen as the EGFR inhibitor because the combination of platinum based therapy with cetuximab is effective in lung and head and neck cancers. In addition the safety and activity of carboplatinpaclitaxel with ASA 404 has already been demonstrated. A weekly schedule of ASA is chosen because 1 the safety of the weekly schedule has been tested 2 preclinical studies confirm enhanced activity with frequent administration 3 provides an opportunity to evaluate the safety and pharmacokinetics of ASA 404 with weekly cetuximab. 